REZZOLA, SARA
 Distribuzione geografica
Continente #
NA - Nord America 4.818
AS - Asia 1.757
EU - Europa 1.542
SA - Sud America 297
Continente sconosciuto - Info sul continente non disponibili 146
AF - Africa 54
OC - Oceania 5
Totale 8.619
Nazione #
US - Stati Uniti d'America 4.645
SG - Singapore 598
CN - Cina 500
IT - Italia 336
BR - Brasile 231
DE - Germania 200
PL - Polonia 200
UA - Ucraina 198
HK - Hong Kong 196
FI - Finlandia 129
GB - Regno Unito 120
VN - Vietnam 113
BD - Bangladesh 100
CA - Canada 89
FR - Francia 84
IN - India 68
RU - Federazione Russa 67
TR - Turchia 51
IE - Irlanda 50
AR - Argentina 26
SE - Svezia 25
CZ - Repubblica Ceca 23
JP - Giappone 23
NL - Olanda 23
ES - Italia 22
ZA - Sudafrica 22
ID - Indonesia 20
MX - Messico 18
IQ - Iraq 15
BE - Belgio 14
AT - Austria 13
JM - Giamaica 13
IL - Israele 12
CO - Colombia 11
CR - Costa Rica 10
MA - Marocco 10
EC - Ecuador 9
LT - Lituania 9
TT - Trinidad e Tobago 9
PK - Pakistan 8
VE - Venezuela 8
PH - Filippine 6
CH - Svizzera 5
CU - Cuba 5
DZ - Algeria 5
RO - Romania 5
SA - Arabia Saudita 5
SV - El Salvador 5
TN - Tunisia 5
AU - Australia 4
BS - Bahamas 4
NG - Nigeria 4
TW - Taiwan 4
UY - Uruguay 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CL - Cile 3
EE - Estonia 3
GD - Grenada 3
GP - Guadalupe 3
GR - Grecia 3
GT - Guatemala 3
IR - Iran 3
KE - Kenya 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BB - Barbados 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
EU - Europa 2
HR - Croazia 2
HU - Ungheria 2
JO - Giordania 2
LB - Libano 2
LK - Sri Lanka 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BG - Bulgaria 1
BM - Bermuda 1
HN - Honduras 1
KH - Cambogia 1
KZ - Kazakistan 1
LV - Lettonia 1
MG - Madagascar 1
MU - Mauritius 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SC - Seychelles 1
Totale 8.474
Città #
Ashburn 609
Fairfield 330
Singapore 329
San Jose 282
Warsaw 198
Hong Kong 193
New York 181
Woodbridge 162
Houston 157
Los Angeles 152
Chandler 151
Jacksonville 143
Beijing 138
Seattle 122
Wilmington 112
Cambridge 111
Dallas 111
Council Bluffs 108
Ann Arbor 106
The Dalles 101
Brescia 94
Munich 86
Princeton 82
Helsinki 80
San Francisco 67
Dublin 50
Santa Clara 50
Lauterbourg 43
Dearborn 42
Chicago 41
Istanbul 40
Denver 38
Montreal 38
Ho Chi Minh City 36
Nanjing 36
Orem 35
Brooklyn 34
São Paulo 34
Atlanta 32
Shanghai 31
Phoenix 28
Buffalo 27
Milan 26
London 24
Turku 24
Columbus 23
Tokyo 22
Des Moines 20
Redondo Beach 20
Hanoi 19
Toronto 19
Moscow 18
Brno 16
Jakarta 16
Nanchang 16
North Bergen 16
San Diego 16
Boston 15
Chennai 15
Stockholm 15
Jinan 14
Manchester 14
Amsterdam 13
Brussels 12
Frankfurt am Main 12
Lancaster 12
Rome 12
Washington 12
Hebei 11
Johannesburg 11
Shenyang 11
Changsha 10
Dong Ket 10
Lappeenranta 9
Miami 9
Mumbai 9
Charlotte 8
Guangzhou 8
Nuremberg 8
Poplar 8
Raleigh 8
Baghdad 7
Barcelona 7
Genoa 7
Kingston 7
Mexico City 7
Naples 7
Rio de Janeiro 7
Tianjin 7
Boardman 6
Calgary 6
Cremona 6
Detroit 6
Düsseldorf 6
Las Vegas 6
Minneapolis 6
Napoli 6
Pescara 6
Prague 6
Queens 6
Totale 5.523
Nome #
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer 915
A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers 314
Long pentraxin-3 follows and modulates bladder cancer progression 231
d-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3 229
Antiangiogenic effectiveness of the urokinase receptor- derived peptide UPARANT in a model of oxygen-induced retinopathy 217
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 207
3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy 199
Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis 198
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy 198
Diabetic retinopathy: Vascular and inflammatory disease 197
Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumor infiltration and angiogenesis 190
Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases 183
Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications 180
Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy 179
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors 169
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 168
A novel ex vivo murine retina angiogenesis (EMRA) assay 152
In vitro and ex vivo retina angiogenesis assays 152
The autocrine fgf/fgfr system in both skin and uveal melanoma: Fgf trapping as a possible therapeutic approach 152
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 152
Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy 151
Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications 151
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer 148
lnvolvement of N-formyl peptide receptors in modulating the pro-angiogenic pro-inflammatory activity of human vitreous in proliferative diabetic retinopathy (POR) 142
CARD11 dominant negative mutation leads to altered human Natural Killer cell homeostasis 141
VEGFR2 activation mediates the pro-angiogenic activity of BMP4 140
Anti-angiogenic activity of the urokinase receptor-derived peptide UPARANT 139
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer 139
Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform 138
Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey? 135
Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in Müller cells 134
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies 130
An orthotopic model of uveal melanoma in zebrafish embryo: A novel platform for drug evaluation 128
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer 123
The Urokinase Receptor-Derived Peptide UPARANT Inhibits Pathological Retinal Angiogenesis 119
Pentraxin 3 inhibits the angiogenic potential of multiple myeloma cells 119
Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives 117
Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines 116
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress 113
FGF-trapping hampers cancer stem-like cells in uveal melanoma 111
Diabetic Retinopathy: Soluble and Imaging Ocular Biomarkers 109
Cancer stem-like cells in uveal melanoma: novel insights and therapeutic implications 109
The FGF/FGFR System in the Physiopathology of the Prostate Gland 109
Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma 107
The vitreous humor from proliferative diabetic retinopathy patients: translational implications 101
Benzenesulfonamides with different rigidity-conferring linkers as carbonic anhydrase inhibitors: an insight into the antiproliferative effect on glioblastoma, pancreatic, and breast cancer cells 97
In Vitro and In Vivo Efficacy on Retinal Neo-Vascularization of an Innovative Broad-Range Anti-Angiogenic Synthetic Peptide (Uparant) 96
Lack of DOCK8 impairs the primary biologic functions of human NK cells and abrogates CCR7 surface expression in a WASP-independent manner 95
A novel mertansine conjugate for acid-reversible targeted drug delivery validated through the Avidin-Nucleic-Acid-NanoASsembly platform 92
Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis 89
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination 86
Vegf‐independent activation of müller cells by the vitreous from proliferative diabetic retinopathy patients 78
The lymphatic vasculature: An active and dynamic player in cancer progression 56
Differentiation of human hyalocytes from induced pluripotent stem cells through ascorbic acid treatment 51
Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas 46
Heparin-binding Proteins Drive The Resistance To Anti-VEGF Therapies In Diabetic Retinopathy 25
Cancer Stem-like Cells: a new therapeutic target for the treatment of metastatic uveal melanoma 21
Involvement of N-formyl peptide receptors in modulating the pro-angiogenic/pro-inflammatory activity of human vitreous in proliferative diabetic retinopathy (PDR) 21
Role of heparin-binding mediators in the resistance to anti-VEGF therapies in diabetic retinopathy 15
Totale 8.619
Categoria #
all - tutte 40.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.411


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022294 0 0 0 18 6 20 33 25 31 41 33 87
2022/2023427 61 16 22 22 53 90 4 45 58 3 32 21
2023/2024583 38 10 79 30 31 122 27 27 99 31 17 72
2024/20251.116 15 13 16 148 96 109 101 85 110 59 192 172
2025/20262.667 261 271 156 340 272 178 370 102 121 217 112 267
2026/20271.333 675 134 161 363 0 0 0 0 0 0 0 0
Totale 8.619